Details

Autor(en) / Beteiligte

• Wang, Ying-Qing
• Wang, Ping-Yuan
• Wang, Yu-Ting
• Yang, Guang-Fu
• Zhang, Ao
• Miao, Ze-Hong

Titel

An Update on Poly(ADP-ribose)polymerase‑1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

Ist Teil von

• Journal of medicinal chemistry, 2016-11, Vol.59 (21), p.9575-9598

Ort / Verlag

United States: American Chemical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Poly­(ADP-ribose)­polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug that selectively kills cancer cells by targeting homologous recombination repair defects. Since 2010, important advances have been achieved in PARP-1 inhibitors. Specifically, the approval of olaparib in 2014 for the treatment of ovarian cancer with BRCA mutations validated PARP-1 as an anticancer target and established its clinical importance in cancer therapy. Here, we provide an update on PARP-1 inhibitors, focusing on breakthroughs in their clinical applications and investigations into relevant mechanisms of action, biomarkers, and drug resistance. We also provide an update on the design strategies and the structural types of PARP-1 inhibitors. Opportunities and challenges in PARP-1 inhibitors for cancer therapy will be discussed based on the above advances.